Pci Biotech As
🇸🇪Sweden
PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer
Phase 2
Terminated
- Conditions
- Cholangiocarcinoma
- Interventions
- Drug: Gemcitabine/Cisplatin chemotherapy
- First Posted Date
- 2019-09-23
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- PCI Biotech AS
- Target Recruit Count
- 41
- Registration Number
- NCT04099888
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇩🇰Odense Universitetshospital, Odense, Denmark
🇺🇸The Mayo Clinic Hospital - Saint Mary's Campus, 1216 Second Street Southwest, Rochester, Minnesota, United States
Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Biological: Hiltonol (Poly-ICLC)Biological: HPV E7 (Human Papilloma Virus E7) peptidesBiological: KLH (Keyhole Limpet Hemocyanin)
- First Posted Date
- 2016-10-28
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- PCI Biotech AS
- Target Recruit Count
- 96
- Registration Number
- NCT02947854
- Locations
- 🇬🇧
Covance Clinical Research Unit Limited, Leeds, United Kingdom
A Phase I/II Safety and Efficacy Study of PCI of Gemcitabine and Chemotherapy in Patients With Cholangiocarcinomas
Phase 1
Completed
- Conditions
- Cholangiocarcinoma
- Interventions
- Drug: Amphinex, Gemcitabine and Cisplatin
- First Posted Date
- 2013-07-16
- Last Posted Date
- 2019-10-29
- Lead Sponsor
- PCI Biotech AS
- Target Recruit Count
- 24
- Registration Number
- NCT01900158
- Locations
- 🇫🇷
CHU Angers, Angers, Maine-et-Loire, France
🇩🇪Universitätsklinikum Leipzig, Leipzig, Sachsen, Germany
🇩🇪Klinikum der Ludwig-Maximilians-Universität, München, Bayern, Germany
Dose Escalating Study for Amphinex-based PCI of Bleomycin.
Phase 1
Completed
- Conditions
- Cutaneous or Sub-cutaneous Malignancies
- Interventions
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2014-06-16
- Lead Sponsor
- PCI Biotech AS
- Target Recruit Count
- 3
- Registration Number
- NCT01872923
- Locations
- 🇬🇧
University College London Hospital, London, United Kingdom
A Study to Evaluate the Safety and Efficacy of Amphinex Induced PCI of Bleomycin for Recurrent Head and Neck Cancer.
Phase 2
Terminated
- Conditions
- Recurrent Head and Neck CancerCarcinoma, Squamous Cell of Head and Neck
- Interventions
- First Posted Date
- 2012-05-25
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- PCI Biotech AS
- Target Recruit Count
- 26
- Registration Number
- NCT01606566
- Locations
- 🇩🇪
Universitätsklinikum Schleswig-Holstein, Lübeck, Schleswig-Holstein, Germany
🇫🇷CHU de Nantes Hôtel Dieu, Nantes, Nantes Cedex 1, France
🇫🇷Centre Alexis Vautrin (CAV)-Nancy Université, Nancy, France
Safety Study of Amphinex Based Photochemical Internalisation (PCI) of Bleomycin in Patients With Cutaneous Cancer
Phase 1
Completed
- Conditions
- Skin NeoplasmsHead and Neck Neoplasms
- Interventions
- First Posted Date
- 2009-10-12
- Last Posted Date
- 2019-04-29
- Lead Sponsor
- PCI Biotech AS
- Target Recruit Count
- 19
- Registration Number
- NCT00993512
- Locations
- 🇬🇧
University College London Hospital, London, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath